Update on antifungals targeted to the cell wall: Focus on β-1,3-glucan synthase inhibitors

Expert Opinion on Investigational Drugs

Volumn 10, Issue 2, 2001, Pages 269-280

  Georgopapadakou, N H ^a  

^a DUPONT COMPANY   (United States)

Author keywords

Anidulafungin; Benanomicin; Caspofungin; Chitin synthase; Echinocandins; Fungal cell wall; Glucan synthase; Micafungin; Nikkomycin; Pradimicin

Indexed keywords

1,3 BETA GLUCAN SYNTHASE; 1,3 BETA GLUCAN SYNTHASE INHIBITOR; A 19421129; AEROTHRICIN; ANIDULAFUNGIN; ANTIFUNGAL AGENT; AROMATIC COMPOUND; BENANOMICIN A; CANSIDAS; CASPOFUNGIN; CHITIN SYNTHASE; DRUG ANALOG; ECHINOCHANDIN; ENZYME INHIBITOR; FR 901469; LIPOPEPTIDE; LY 307853; LY 329960; LY 333006; MANNOPROTEIN; MICAFUNGIN; MULUNDOCANDIN; NATURAL PRODUCT; NIKKOMYCIN; NIKKOMYCIN Z; ORGANOPHOSPHATE; PRADIMICIN; PRADIMICIN C; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; XANTHOFULVIN;

ADULT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ANTIFUNGAL ACTIVITY; ARTICLE; CELL WALL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DISTRIBUTION VOLUME; DRUG CLEARANCE; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG SELECTIVITY; FEMALE; FUNGICIDAL ACTIVITY; HUMAN; MALE; MOUSE; MYCOSIS; NONHUMAN;

ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; BETA-GLUCANS; CELL WALL; CHITIN SYNTHASE; ENZYME INHIBITORS; GLUCANS; GLUCOSYLTRANSFERASES; LIPOPROTEINS; PEPTIDES; PEPTIDES, CYCLIC;

EID: 0035147071     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.10.2.269     Document Type: Article

References (121)

1. Fungal infections: A growing threat
2. New and emerging yeast pathogens
3. National surveillance of nosocomial blood stream infection due to Candida albicans: Frequency of occurrence and antifungal susceptibility in the SCOPE Program
4. Early diagnosis of invasive aspergillosis
5. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation
6. The treatment of infection due to Pneumocystis carinii
7. Human mycoses: Drugs and targets for emerging pathogens
8. Antifungal agents: Chemotherapeutic targets and immunologic strategies
9. Antifungals: Mechanism of action and resistance, established and novel drugs
10. Importance of antifungal drug resistance: Clinical significance and need for novel therapy
11. Current and emerging azole antifungal agents
12. Clinical, cellular and molecular factors that contribute to antifungal drug resistance
13. Update on drug interactions with azole antifungal agents
14. Lipid formulations of amphotericin B: Clinical efficacy and toxicities
15. Nosocomial candidiasis: Emerging species, reservoirs and modes of transmission
16. Antifungal resistance in non-albicans Candida species
17. Molecular basis of cell integrity and morphogenesis in Saccharomyces cerevisiae
18. The yeast cell wall, a dynamic structure engaged in growth and morphogenesis
19. Cell wall dynamics in yeast
20. Cell wall maintenance in fungi
21. The fungal cell wall as a drug target
22. Antifungals targeted to the cell wall
23. Cell-wall active antifungals and emerging targets
24. Cell wall protein mannosylation determines Candida albicans cell surface hydrophobicity
25. Alterations to the cell wall of Histoplasma capsulatum yeasts during infection of macrophages or epithelial cells
26. Alteration of cell wall composition leads to amphotericin B resistance in Aspergillus flavus
27. Classification of fungal chitin synthases
28. Genetics and molecular biology of chitin synthesis in fungi
29. Role of three chitin synthase genes in the growth of Candida albicans
30. A hyphal-specific chitin synthase gene (CHS2) is not essential for growth, dimorphism, or virulence of Candida albicans
31. Attenuated virulence of chitin-deficient mutants of Candida albicans
32. Molecular analysis of Chs3p participation in chitin synthase III activity
33. Increase in chitin as an essential response to defects in assembly of cell wall polymers in the ggp1delta mutant of Saccharomyces cerevisiae
34. Drug interaction studies of a glucan synthase inhibitor (LY 303366) and a chitin synthase inhibitor (nikkomycin Z) for inhibition and killing of fungal pathogens
35. A multigene family related to chitin synthase genes of yeast in the opportunistic pathogen Aspergillus fumigatus
36. Differential expression and function of two homologous subunits of yeast 1,3-β-d-glucan synthase
37. The Saccharomyces cerevisiae FKS1 (ETG1) gene encodes an integral membrane protein which is a subunit of 1,3-β-d-glucan synthase
38. Rho1p, a yeast protein at the interface between cell polarization and morphogenesis
39. Role of small G proteins in yeast cell polarization and wall biosynthesis
40. A glucan synthase FKS1 homolog in Cryptococcus neoformans is single copy and encodes an essential function
41. Molecular cloning and characterization of a glucan synthase gene from the human pathogenic fungus Paracoccidioides brasiliensis
42. Architecture of the yeast cell wall. β(1 → 6)-glucan interconnects mannoprotein, β(1 → 3)-glucan and chitin
43. The Candida albicans KRE9 gene is required for cell wall β-1,6-glucan synthesis and is essential for growth on glucose
44. β-1,6-Glucan synthesis in Saccharomyces cerevisiae
45. Identification of a putative α-glucan synthase essential for cell wall construction and morphogenesis in fission yeast
46. The cell wall architecture of Candida albicans wild-type cells and cell wall-defective mutants
47. Protein O-glycosylation in yeast. The PMT2 gene specifies a second protein O-mannosyltransferase that functions in addition to the PMT1-encoded activity
48. The Ktr1p, Ktr3p and Kre2p/Mnt1p mannosyltransferases participate in the elaboration of yeast O- and N-linked carbohydrate chains
49. Completion of the Saccharomyces cerevisiae genome sequence allows identification of KTR5, KTR6 and KTR7 and definition of the nine-membered KRE2/MNT1 mannosyltransferase gene family in this organism
50. Fungal cell wall inhibitors: Emphasis on clinical aspects
51. Echinocandins and pneumocandins - A new antifungal class with a novel mode of action
52. Lipopeptide inhibitors of fungal glucan synthase
53. Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-β-d-glucan synthase inhibitors
54. Characterization of echinocandin-resistant mutants of Candida albicans: Genetic, biochemical and virulence studies
55. Nikkomycin Z supersensitivity of an echinocandin-resistant mutant of Saccharomyces cerevisiae
56. Fusacandins A and B; novel antifungal antibiotics of the papulacandin class from Fusarium sambucinum. II. Isolation and structural elucidation
57. Discovery of saricandin, a novel papulacandin, from a Fusarium species
58. Mer-WF3010, a new member of the papulacandin family. II. Structure determination
59. BE-29602, a new member of the papulacandin family
60. Discovery of novel antifungal (1,3)-β-d-glucan synthase inhibitors
61. In vitro activity of L-743,872 against putatively amphotericin B (AmB) and fluconazole (Flu)-resistant Candida isolates
62. Antifungal susceptibility testing og Merck L-743,872 against a broad range of fungi
63. In vitro preclinical evaluation studies with pneumocandin antifungal L-743,872
64. In vitro antifungal activity of L-743,872 against a variety of moulds
65. A study of in vitro activity of L-743,872 against Fusarium
66. In vitro synergy of pneumocandin L-743,872 with fluconazole and amphotericin B against Cryptococcus neoformans
67. Evaluation of water soluble pneumocandin L-743,872 in mouse models of disseminated aspergillosis, candidiasis and cryptococcosis
68. Evaluation of L-743,872 in neutropenic mouse models of disseminated candidiasis and aspergillosis
69. Low doses of the pneumocandin L-743,872 are effective for prevention and treatment in an animal model of pulmonary aspergillosis
70. Efficacy of semisynthetic pneumocandin analog L-743,872 against Pneumocystis carinii in murine models
71. Evaluation of L-743,872 (872) in the treatment of murine histoplasmosis
72. Treatment of histoplasmosis with MK-991 (L-743,872)
73. Pharmacokinetics of L-743,872 in the mouse, rat, rhesus and chimpanzee
74. In vitro antifungal activity of FK463, a novel water-soluble echinocandin-like lipopeptide
75. Efficacy of FK463, a novel water-soluble echinocandin-like lipopeptide in murine models of disseminated candidiasis
76. Efficacy of FK463, a novel water-soluble echinocandin-like lipopeptide, in murine models of pulmonary aspergillosis
77. Pharmacokinetics of FK463, a novel water-soluble echinocandin-like lipopeptide, in animals
78. Glucan biosynthesis as a target for antifungals: The echinocandin class of antifungal agents
79. Influence of human serum on Candida species susceptibility to LY303366
80. Efficacy of LY303,366 against amphotericin B. 'susceptible' and 'resistant' A. fumigatus infection in an immunocompromised murine model
81. Comparison of the antifungal in vitro activity of three new antifungal agents against yeast pathogens
82. Noncompartmental single dose plasma pharmacokinetics of the novel echinocandin LY 303366 in rabbits
83. Water soluble echinocandin analogs 1. - Design and synthesis of phosphate, phosphonate and amino acid esters of LY303366
84. Water soluble echinocandin analogs 2. - Design and synthesis of polar hemiaminal ethers
85. Mulundocandin, an echinocandin-like lipopeptide antifungal agent: Biological activities in vitro
86. Synthesis and antifungal activities of cyclopeptamines. Novel cell wall synthesis inhibitors
87. Cellular uptake, localization and activity of A172013, a synthetic cyclopeptamie, in fungi
88. Efficacy of A-175800.0, an inhibitor of fungal cel wall synthesis, against experimental systemic candidiasis
89. In vitro activity of A-192411.29, a novel antifungal lipopeptide
90. FR901469, a novel antifungal antibiotic from an unidentified fungus no. 11243. I. Taxonomy, fermentation, isolation, physico-chemical properties and biological properties
91. FR901469, a novel antifungal antibiotic from an unidentified fungus no. 11243. II. In vitro and in vivo activities
92. Efficacy of nikkomycin Z against experimental pulmonary blastomycosis
93. Efficacy of nikkomycin Z in the treatment of murine histoplasmosis
94. Comparison of nikkomycin Z with amphotericin B and itraconazole for treatment of histoplasmosis in a murine model
95. z by mutasynthesis with genetically engineered Streptomyces tendae TU9001
96. Synthesis and structure-activity relationships of novel fungal chitin synthase inhibitors
97. Pradimicins: A novel class of broad-spectrum antifungal compounds
98. Mode of antifungal action of benanomicin A in Saccharomyces cerevisiae
99. Binding of benanomicin A to fungal cells in reference to its fungicidal action
100. In vitro antifungal and fungicidal spectra of a new pradimicin derivative, BMS-181184
101. Pradimicin therapy of disseminated Candida tropicalis infection in the mouse
102. Antifungal activity of the pradimicin derivative BMS 181184 in the treatment of experimental pulmonary aspergillosis in persistently neutropenic rabbits
103. Successful treatment of Pneumocystis carinii pneumonia in mice with benanomicin A (ME1451)
104. Comparative in vitro susceptibility of clinical trial isolates to the ehinocandin antifungal MK-991
105. A randomized, double-blind, multicenter trial of MK-991 (L-743,872) vs. amphotericin B (AMB) in the treatment of Candida esophagitis in adults
106. Phase I study of FK463, a new antifungal agent, in healthy adult male volunteers
107. Maximum tolerated dose and pharmacokinetics of FK 463 in combination with fluconazole for the prophylaxis of fungal infections in adult bone marrow or peripheral stem cell transplant patients
108. A multicenter study to determine the minimal effective dose of FK463 for the treatment of esophageal candidiasis in HIV-positive patients
109. LY303366 single dose pharmacokinetics and safety in healthy male volunteers
110. LY303366 single intravenous dose pharmacokinetics and safety in healthy volunters
111. Pharmacokinetics of LY303366 in healthy and HIV-infected colunteers after single-dose oral administration
112. Phase I dose optimization study for V-echinocandin
113. Phase II, randomized, open label study of two intravenous dosing regimens of V-echinocandin in the treatment of esophageal candidiasis
114. In vitro antifungal activity of nikkomycin Z in combination with fluconazole or itraconazole
115. From the surface to the inner layer of the fungal cell wall
116. Molecular organization of the alkali-insoluble fraction of Aspergillus fumigatus cell wall
117. A role for the MAP kinase gene MKC1 in cell wall construction and morphological transitions in Candida albicans
118. Involvement of the C terminus in intramolecular nitrogen channeling in glucosamine 6-phosphate synthase: Evidence from a 1.6 A crystal structure of the isomerase domain
119. A spheroplast rate assay for determination of cell wall integrity in yeast
120. A large-scale sonication assay for cell wall mutant analysis in yeast
121. Dansyl N-acetyl glucosamine as a precursor of fluorescent chitin: A method to detect fungal cell wall inhibitors